{"id":"NCT03524092","sponsor":"Eli Lilly and Company","briefTitle":"A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-19","primaryCompletion":"2021-11-03","completion":"2024-12-13","firstPosted":"2018-05-14","resultsPosted":"2022-11-25","lastUpdate":"2025-02-04"},"enrollment":1177,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"DRUG","name":"Mirikizumab SC","otherNames":["LY3074828"]},{"type":"DRUG","name":"Mirikizumab IV","otherNames":["LY3074828"]},{"type":"DRUG","name":"Placebo SC","otherNames":[]}],"arms":[{"label":"Maintenance Period: Miri Induction Responder (IR) - Placebo (PBO) Subcutaneous (SC)","type":"PLACEBO_COMPARATOR"},{"label":"Maintenance Period: Miri IR - 200 Milligram (mg) Miri SC","type":"EXPERIMENTAL"},{"label":"Maintenance Period: PBO IR - PBO SC","type":"OTHER"},{"label":"Loss of Response (LOR) Rescue Period:LOR Cohort-300 mg Miri IV","type":"OTHER"},{"label":"Extended Induction: Induction Nonresponders - 300mg Miri IV","type":"OTHER"},{"label":"Open Label Maintenance: Delayed Responders - 200 mg Miri SC","type":"OTHER"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical responders in the prior 12-week induction study LUCENT-1 (NCT03518086).","primaryOutcome":{"measure":"Percentage of Participants in Clinical Remission at Week 40","timeFrame":"Week 40","effectByArm":[{"arm":"Maintenance Period: Miri IR - PBO SC","deltaMin":25.1,"sd":null},{"arm":"Maintenance Period: Miri IR - 200 mg Miri SC","deltaMin":49.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":385,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","China","Czechia","Denmark","France","Germany","Hungary","India","Ireland","Israel","Italy","Japan","Latvia","Lithuania","Malaysia","Mexico","Netherlands","Poland","Romania","Russia","Serbia","Slovakia","South Korea","Spain","Switzerland","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["40591171","40589947","40071779","39448057","38869019","38313767","38034882","37610533","37379135","37057827"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/6R2qUhQWcgImGasYaaGmYq"]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":192},"commonTop":["Colitis ulcerative","Nasopharyngitis","Arthralgia","Headache","Anaemia"]}}